Bone & Joint Health

Rousselot reveals Peptan collagen peptides and bone study results

A new study led by Rousselot and INRA presents scientific evidence that Peptan collagen peptides improve overall bone health by simultaneously targ...

Omya launches new Calcipur DC range

Calcipur DC can be used as an active ingredient in nutraceuticals and as a diluent in pharmaceuticals

Rousselot brings new perspectives for pharma and nutra applications

Leading global producer of gelatin and collagen peptides, Rousselot, has announced that it will reveal two new products at its 2018 Innovation Days

Making bone health supplements palatable

Martin Koeberle and Verena Garsuch of HERMES PHARMA explore the challenges associated with bringing more convenient combined calcium/vitamin D3 bon...

Helsinn Investment Fund leads financial round in GreenBone

New fund backed by the Helsinn Group, focused on supporting early stage opportunities in areas of high unmet patient need

Novel Nanobody to begin clinical development in osteoarthritis

Ablynx to receive €15m milestone payment from Merck

Gout – pegloticase

Drugs such as allopurinol and probenecid can be used to reduce uric acid levels, but do not work in all patients

Pharnext begins partnership with Tasly, Chinese pharma group

Partnership will exploit the potential of modernised Chinese traditional medicine to make new drug combinations

Sanofi and Regeneron receive CHMP positive opinion for Kevzara

Kevzara (sarilumab) can be used to treat adult patients with moderately to severely active rheumatoid arthritis

Collaboration to identify relapse triggers of Rheumatoid Arthritis

Oxford BioDynamics collaboration to identify biological factors that trigger disease relapses in Rheumatoid Arthritis

Rheumatoid arthritis market to hit $28.5bn by 2025

The rheumatoid arthritis space across 8MM will grow from $19.5bn in 2015, representing a compound annual growth rate of 3.9%, according to GlobalData

Breaking News